Intragastric satiety-inducing device reduces food intake and suppresses body weight gain in a rodent model

Luo, Yin-Gen; Zhang, Xiaowu; Tsauo, Jiaywei; Jung, Hwoon‐Yong; Song, Ho-Young; Zhao, He; Li, Jingui; Gong, Tao; Song, Peng; Xiao, Li

doi:10.1007/s00464-020-07467-x

Cited by 7 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is a major public health concern globally and is linked to various metabolic and psychological problems, such as heart disease, stroke, diabetes, hypertension, and sleep disorders. − Endoscopic bariatric therapies, including intragastric balloons, endoscopic suturing devices, full sense devices, and bypass liners, have been developed as alternatives to bariatric surgery for high-risk obese patients and those who refuse surgery. − Recently, a new version named the intragastric satiety-inducing device (ISD) was developed and evaluated in rat and porcine models. − The ISD reduced food intake and suppressed weight gain with reduced ghrelin hormone levels . However, device-related esophagogastric reflux, a high risk of migration into the stomach, and device-induced reversible inflammatory reaction with tissue hyperplasia were reported. , Although antimigration designs (i.e., barbs, flaps, and antireflux valves) were applied, these device-related complications were still inevitable …”

Section: Introductionmentioning

confidence: 99%

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Lee

Kim

Park

et al. 2022

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Bariatric surgery is the most effective treatment for weight recidivism, and endoscopic bariatric treatment has been developed for a similar effect without anatomical modification. An intragastric satiety-inducing device (ISD) is a minimally invasive approach to induce satiety by continuously pressing the stomach and stimulating ghrelin-producing cells. To enhance the therapeutic effects of ISD, photodynamic therapy (PDT) can be combined by generating singlet oxygen under laser irradiation. Methylene blue (MB), as a photosensitizer (PS), was coated on the ISD surface for singlet oxygen production to stimulate or destroy cells. Ghrelin-producing cells effectively inhibited ghrelin secretion and induced gastrointestinal satiety signals compared with the MB-uncoated device via PDT. Herein, MB-embedded ISDs were developed, and their photoresponsive abilities were demonstrated in the device itself and in vitro. PDT with an MB-embedded ISD was successfully performed in a porcine model, which had 2-fold reduced body weight gain (12% in PDT vs 24% in control) and 2-fold reduced ghrelin levels (21.2 pg/mL in PDT vs 45.1 pg/mL in control) at the first week postprocedure. The simple and unique operation extends the point of view in PDT and is expected to be a novel endoscopic bariatric therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Lee

Kim

Park

et al. 2022

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…In medaka and zebrafish models, leptin-receptor deficiency also elicited an increased food intake pattern with a normal growth rate [57,58]. Because the energy homeostasis controlling system is highly complicated, simply increasing food intake might not explain the causal relationship with an acceleration of the growth rate or with weight gain [59][60][61]. In the Alamar Blue metabolic assay, we observed that the α-MSH mutant decreased energy expenditure by decreasing its metabolic rate (Figure 3D).…”

Section: Discussionmentioning

confidence: 93%

Depletion of Alpha-Melanocyte-Stimulating Hormone Induces Insatiable Appetite and Gains in Energy Reserves and Body Weight in Zebrafish

et al. 2021

View full text Add to dashboard Cite

The functions of anorexigenic neurons secreting proopiomelanocortin (POMC)/alpha-melanocyte-stimulating hormone (α-MSH) of the melanocortin system in the hypothalamus in vertebrates are energy homeostasis, food intake, and body weight regulation. However, the mechanisms remain elusive. This article reports on zebrafish that have been genetically engineered to produce α-MSH mutants, α-MSH−7aa and α-MSH−8aa, selectively lacking 7 and 8 amino acids within the α-MSH region, but retaining most of the other normal melanocortin-signaling (Pomc-derived) peptides. The α-MSH mutants exhibited hyperphagic phenotypes leading to body weight gain, as observed in human patients and mammalian models. The actions of several genes regulating appetite in zebrafish are similar to those in mammals when analyzed using gene expression analysis. These include four selected orexigenic genes: Promelanin-concentrating hormone (pmch), agouti-related protein 2 (agrp2), neuropeptide Y (npy), and hypothalamic hypocretin/orexin (hcrt). We also study five selected anorexigenic genes: Brain-derived neurotrophic factor (bdnf), single-minded homolog 1-a (sim1a), corticotropin-releasing hormone b (crhb), thyrotropin-releasing hormone (trh), and prohormone convertase 2 (pcsk2). The orexigenic actions of α-MSH mutants are rescued completely after hindbrain ventricle injection with a synthetic analog of α-MSH and a melanocortin receptor agonist, Melanotan II. We evaluate the adverse effects of MSH depletion on energy balance using the Alamar Blue metabolic rate assay. Our results show that α-MSH is a key regulator of POMC signaling in appetite regulation and energy expenditure, suggesting that it might be a potential therapeutic target for treating human obesity.

show abstract

New Technologies to Treat Obesity and Related Comorbidities

Brunaldi

Neto²

2023

The SAGES Manual Operating Through the Endoscope

View full text Add to dashboard Cite

Intragastric satiety-inducing device reduces food intake and suppresses body weight gain in a rodent model

Cited by 7 publications

References 21 publications

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Photodynamic Methylene Blue-Embedded Intragastric Satiety-Inducing Device to Treat Obesity

Depletion of Alpha-Melanocyte-Stimulating Hormone Induces Insatiable Appetite and Gains in Energy Reserves and Body Weight in Zebrafish

New Technologies to Treat Obesity and Related Comorbidities

Contact Info

Product

Resources

About